Newly Formed Company, atHeart Medical, Aims to Evolve Septal Closure with the reSept™ ASD Occluder

Newly Formed Company, atHeart Medical, Aims to Evolve Septal Closure with the reSept™ ASD Occluder
Company prepares for U.S. IDE clinical trial of its novel metal-free frame designed to reduce complications and preserve long-term treatment options
News provided by
Share this article
Share this article
BAAR, Switzerland and MOUNTAIN VIEW, Calif., April 20, 2021 /PRNewswire/ -- atHeart Medical, a medical device company dedicated to establishing the new standard of care for closure of atrial septal defects (ASD), announced today that it has commenced operations and is initiating its U.S. Investigational Device Exemption (IDE) trial. The company is led by seasoned global medtech executive, Laurent Grandidier, with support from an exceptional management team that has decades of experience with medical device start-ups and major corporations.

Related Keywords

Florida , United States , Switzerland , Swiss , Larry Latson , Laurent Grandidier , Katie Arnold , Olle Larsson Holding , Company Data On File , Heart Medical , Co Principal Investigator , Pediatric Interventional Cardiology , Joe Dimaggio Children , புளோரிடா , ஒன்றுபட்டது மாநிலங்களில் , சுவிட்சர்லாந்து , சுவிஸ் , கேடீ அர்னால்ட் , ஒல்லெ லார்சன் வைத்திருத்தல் , இதயம் மருத்துவ , இணை ப்ரிந்ஸிபல் புலனாய்வாளர் , குழந்தை தலையீடு இருதயவியல் , ஓஹோ திமஃகிஓ குழந்தைகள் ,